PT4028017T - Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunes - Google Patents

Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunes

Info

Publication number
PT4028017T
PT4028017T PT207888686T PT20788868T PT4028017T PT 4028017 T PT4028017 T PT 4028017T PT 207888686 T PT207888686 T PT 207888686T PT 20788868 T PT20788868 T PT 20788868T PT 4028017 T PT4028017 T PT 4028017T
Authority
PT
Portugal
Prior art keywords
pirazole
nuak1
lrrk2
dihydrobenzo
modulators
Prior art date
Application number
PT207888686T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Origenis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origenis Gmbh filed Critical Origenis Gmbh
Publication of PT4028017T publication Critical patent/PT4028017T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
PT207888686T 2019-09-13 2020-09-11 Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunes PT4028017T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962899908P 2019-09-13 2019-09-13

Publications (1)

Publication Number Publication Date
PT4028017T true PT4028017T (pt) 2024-01-16

Family

ID=72801756

Family Applications (1)

Application Number Title Priority Date Filing Date
PT207888686T PT4028017T (pt) 2019-09-13 2020-09-11 Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunes

Country Status (17)

Country Link
US (1) US20220380374A1 (https=)
EP (2) EP4327884A3 (https=)
JP (2) JP7796007B2 (https=)
KR (1) KR20220062038A (https=)
CN (2) CN114793435B (https=)
AU (1) AU2020344216A1 (https=)
CA (1) CA3154123A1 (https=)
DK (1) DK4028017T3 (https=)
ES (1) ES2969088T3 (https=)
FI (1) FI4028017T3 (https=)
HU (1) HUE065093T2 (https=)
IL (1) IL291335A (https=)
PL (1) PL4028017T3 (https=)
PT (1) PT4028017T (https=)
RS (1) RS65045B1 (https=)
SI (1) SI4028017T1 (https=)
WO (1) WO2021048620A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7796007B2 (ja) * 2019-09-13 2026-01-08 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、LRRK2、NUAK1および/またはTYK2キナーゼモジュレータとしての1,4-ジヒドロベンゾ[d]ピラゾロ[3,4-f][1,3]ジアゼピン誘導体および関連する化合物
JP2022548581A (ja) * 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、LRRK2、NUAK1および/またはTYK2キナーゼモジュレータとしての1,4-ジヒドロベンゾ[d]ピラゾロ[3,4-f][1,3]ジアゼピン誘導体および関連する化合物
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2350086B1 (en) 2008-09-23 2021-04-21 The Johns Hopkins University Fused diimidazodiazepine compounds and methods of use and manufacture thereof
AU2012244549B2 (en) * 2011-04-21 2017-04-20 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
JP7796007B2 (ja) * 2019-09-13 2026-01-08 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、LRRK2、NUAK1および/またはTYK2キナーゼモジュレータとしての1,4-ジヒドロベンゾ[d]ピラゾロ[3,4-f][1,3]ジアゼピン誘導体および関連する化合物
JP2022548581A (ja) 2019-09-13 2022-11-21 オリゲニス ゲーエムベーハー 例えば自己免疫疾患の処置のための、LRRK2、NUAK1および/またはTYK2キナーゼモジュレータとしての1,4-ジヒドロベンゾ[d]ピラゾロ[3,4-f][1,3]ジアゼピン誘導体および関連する化合物

Also Published As

Publication number Publication date
PL4028017T3 (pl) 2024-03-18
CA3154123A1 (en) 2021-03-18
IL291335A (en) 2022-05-01
DK4028017T3 (da) 2024-01-15
SI4028017T1 (sl) 2024-04-30
FI4028017T3 (fi) 2024-01-11
EP4028017B1 (en) 2023-12-06
EP4327884A3 (en) 2024-05-01
HUE065093T2 (hu) 2024-05-28
WO2021048620A1 (en) 2021-03-18
CN114793435A (zh) 2022-07-26
RS65045B1 (sr) 2024-02-29
AU2020344216A1 (en) 2022-03-31
ES2969088T3 (es) 2024-05-16
JP2025081660A (ja) 2025-05-27
JP2022548246A (ja) 2022-11-17
EP4028017A1 (en) 2022-07-20
JP7796007B2 (ja) 2026-01-08
CN114793435B (zh) 2024-10-01
US20220380374A1 (en) 2022-12-01
CN119775277A (zh) 2025-04-08
KR20220062038A (ko) 2022-05-13
EP4327884A2 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
IL291338A (en) 1,4-dihydrobenzo[d]pyrazolo[f-3,4]diazepine derivatives and related compounds as modulators of lrrk2, nuak1 and/or tyk2 kinase for the treatment of diseases such as autoimmune diseases
CL2016001895A1 (es) Compuestos
HUE055334T2 (hu) Szerves vegyületek és azok alkalmazása központi idegrendszeri betegségek kezelésében vagy megelõzésében
BR112018072552A2 (pt) imidazo [1,2-b]piridazinas, imidazo [1,5-b] piridazinas substituídas, compostos relacionados, e seu uso no tratamento de distúrbios médicos
MX378579B (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX394094B (es) PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
PT4028017T (pt) Derivados de 1,4-di-hidrobenzo[d]pirazolo[3,4-f][1,3]diazepina e compostos relacionados como moduladores das cinases lrrk2, nuak1 e/ou tyk2 para o tratamento de, por exemplo, doenças autoimunes
MY193524A (en) Diaryl macrocycles as modulators of protein kinases
IL286340A (en) Topical formulations for treatment of peripheral neuropathies
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
MX389627B (es) Inhibidores de la magl.
BR112017005209A2 (pt) compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso
GEP20257716B (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
BR112021018456A2 (pt) Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
BR112018070586A2 (pt) compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
BR112017001726A2 (pt) compostos de 6,7-di-hidropirazolo [1,5-a]pirazin-4(5h)-ona e seus usos como moduladores alostéricos negativos de receptores mglur2
PH12016502307B1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
BR112017001861A2 (pt) compostos de 6,7-di-hidropirazolo [1,5-a]pirazin-4(5h)-ona e seus usos como moduladores alostéricos negativos de receptores mglur2
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
PT3737684T (pt) Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidin-5-ona e compostos relacionados como moduladores do recetor c5a para tratamento de vasculite e doenças inflamatórias
GB2605422B (en) Treatment of the central nervous system